25th Feb 2015 13:49
LONDON (Alliance News) - AstraZeneca PLC said Wednesday that it has entered into a three-year collaboration deal with UK-based biopharmaceutical company Orca Pharmaceuticals Ltd to develop inhibitors of retinoic acid?related orphan nuclear receptor gamma.
AstraZeneca said inhibitors against this receptor are believed to have potential for the treatment of a wide range of autoimmune diseases.
Under the deal AstraZeneca will gain access to inhibitors developed by Orca and will integrate them into its in-house programme. It also has the option to acquire Orca compounds at the end of the collaboration.
Shares in AstraZeneca are trading down 0.8% at 4,471.50 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca